Sind schon 100% im januar gelaufen!
Was haltet ihr davon?
Was haltet ihr davon?
Top-News
Wie wäre es mit einem Zock mit Orchid C.?
Beiträge:
7
Zugriffe: 5.451 / Heute: 1
Zugriffe: 5.451 / Heute: 1
nach Quartalsbericht mit deutlich reduziertem Verlust und mehreren Kaufempfehlungen Kursziel 17$,Stochstik bereits relativ hoch Alert: UBS Warburg reiterates coverage of ORCH at Buy (Headline only) Briefing.com - 12:49 PM EDT
• Alert: First Union Sec reiterates coverage of ORCH at Strong Buy (Headline only) Briefing.com - 12:42 PM EDT
• Alert: Robertson Stephens reiterates coverage of ORCH at Buy (Headline only) Briefing.com - 12:32 PM EDT
Orchid BioSciences, Inc. (Nasdaq: ORCH) Previous Close: Up 16% to $4.75 on vol.
2,167,400 Shares: ACCUMULATE
Orchid BioSciences, Inc. (Nasdaq: ORCH) announced that it has successfully
performed ultra-high throughput genotyping using its proprietary SNP-IT(TM) SNP
scoring technology on two different instrument platforms. Orchid is the first
company to demonstrate the feasibility of ultra-high throughput SNP scoring on
multiple platforms. Both systems serve as scalable components of Orchid's
MegaSNPatron(TM) facilities that provide SNP scoring services primarily for high
volume users like pharmaceutical and agricultural companies.
Orchid BioSciences recently reported financial results for its first quarter
ended March 31, 2001. Total revenues for the first quarter of 2001 increased to
$5.6 million, up from $3.5 million for the same period in 2000, an increase of
60 percent. The increase in revenues during the first quarter resulted primarily
from placements of SNPstream(R) 25K platforms, sales of SNPware(TM) consumable
kits, sales of single nucleotide polymorphism (SNP) scoring and DNA and other
genetic diversity testing services, collaboration and license fees, and the
addition of Cellmark Diagnostics, which Orchid acquired in February, 2001.
Orchid BioSciences, Inc. is a leading provider of products, services and
technologies for SNP scoring and genetic diversity analyses. Orchid has
developed SNP-IT, its proprietary SNP analysis technology and markets SNPstream
instruments and SNPware(TM) consumables that rapidly generate highly accurate,
cost effective SNP information. SNP-IT is usable in environments ranging from
small-scale laboratories to large commercial facilities. Its versatility also
has enabled Orchid to partner with industry leaders to make SNP-IT-enabled
products available on a wide variety of instrument platforms.
Allerdings neues SECFiling über geplante Kapitalerhöhung!
• Alert: First Union Sec reiterates coverage of ORCH at Strong Buy (Headline only) Briefing.com - 12:42 PM EDT
• Alert: Robertson Stephens reiterates coverage of ORCH at Buy (Headline only) Briefing.com - 12:32 PM EDT
Orchid BioSciences, Inc. (Nasdaq: ORCH) Previous Close: Up 16% to $4.75 on vol.
2,167,400 Shares: ACCUMULATE
Orchid BioSciences, Inc. (Nasdaq: ORCH) announced that it has successfully
performed ultra-high throughput genotyping using its proprietary SNP-IT(TM) SNP
scoring technology on two different instrument platforms. Orchid is the first
company to demonstrate the feasibility of ultra-high throughput SNP scoring on
multiple platforms. Both systems serve as scalable components of Orchid's
MegaSNPatron(TM) facilities that provide SNP scoring services primarily for high
volume users like pharmaceutical and agricultural companies.
Orchid BioSciences recently reported financial results for its first quarter
ended March 31, 2001. Total revenues for the first quarter of 2001 increased to
$5.6 million, up from $3.5 million for the same period in 2000, an increase of
60 percent. The increase in revenues during the first quarter resulted primarily
from placements of SNPstream(R) 25K platforms, sales of SNPware(TM) consumable
kits, sales of single nucleotide polymorphism (SNP) scoring and DNA and other
genetic diversity testing services, collaboration and license fees, and the
addition of Cellmark Diagnostics, which Orchid acquired in February, 2001.
Orchid BioSciences, Inc. is a leading provider of products, services and
technologies for SNP scoring and genetic diversity analyses. Orchid has
developed SNP-IT, its proprietary SNP analysis technology and markets SNPstream
instruments and SNPware(TM) consumables that rapidly generate highly accurate,
cost effective SNP information. SNP-IT is usable in environments ranging from
small-scale laboratories to large commercial facilities. Its versatility also
has enabled Orchid to partner with industry leaders to make SNP-IT-enabled
products available on a wide variety of instrument platforms.
Allerdings neues SECFiling über geplante Kapitalerhöhung!
Aastrom
Biosciences, Inc. (Nasdaq: ASTM) auf die Watchlist,Recherche bei www.quicken.com oder www.clearstation.com möglich,gerade wieder unt 1$ gefallen,sind in der Krebsforschung tätig ,stoppen Tumorwachstum in Versuchsphase II(?)
Biosciences, Inc. (Nasdaq: ASTM) auf die Watchlist,Recherche bei www.quicken.com oder www.clearstation.com möglich,gerade wieder unt 1$ gefallen,sind in der Krebsforschung tätig ,stoppen Tumorwachstum in Versuchsphase II(?)
Aastrom Biosciences Receives Patent
Boston, May 15, 2001 (Midnight Trader via COMTEX) -- Aastrom Biosciences (ASTM)
reported this morning it received a patent for its process for growing and
harvesting human cells ex vivo in a cassette chamber format, without exposing
the cells to the environment. The stock is rising this morning on 4,500 Island
shares.
Boston, May 15, 2001 (Midnight Trader via COMTEX) -- Aastrom Biosciences (ASTM)
reported this morning it received a patent for its process for growing and
harvesting human cells ex vivo in a cassette chamber format, without exposing
the cells to the environment. The stock is rising this morning on 4,500 Island
shares.
schon gestern und heute.Am 16.5. 1,05 heute 2,41 bei rasantem Volumen von 2,9 Millionen,Stochastik allerdings weit oben .Sollte sicher auf die Watchlist.Wie auch Orchid !
ANN ARBOR, Mich. (Dow Jones)--Aastrom Biosciences Inc. (ASTM, news, msgs) and Neoprobe Corp. (NEOP, news, msgs) are collaborating to develop a new immune system cell therapy product to treat cancer.
In a press release Tuesday, the companies said they will use Aastrom's AastromReplicell system and lymphocyte production technologies to produce a therapeutically active product based on Neoprobe's lymph node lymphocyte cell therapy.
Neoprobe said breast and colorectal cancer patients treated with its LNL cell therapy had an extended median survival and an improved response to standard chemotherapy.
Company Web site: www.neoprobe.com
Aastrom develops automated cell therapy technology and devices for cancer patients who have undergone chemotherapy or radiation treatment.
Company Web site: www.aastrom.com
ANN ARBOR, Mich. (Dow Jones)--Aastrom Biosciences Inc. (ASTM, news, msgs) and Neoprobe Corp. (NEOP, news, msgs) are collaborating to develop a new immune system cell therapy product to treat cancer.
In a press release Tuesday, the companies said they will use Aastrom's AastromReplicell system and lymphocyte production technologies to produce a therapeutically active product based on Neoprobe's lymph node lymphocyte cell therapy.
Neoprobe said breast and colorectal cancer patients treated with its LNL cell therapy had an extended median survival and an improved response to standard chemotherapy.
Company Web site: www.neoprobe.com
Aastrom develops automated cell therapy technology and devices for cancer patients who have undergone chemotherapy or radiation treatment.
Company Web site: www.aastrom.com
denn heute wird erwartet,dass Bush trotz der Bedenken Geld für die Forschung genehmigen wird,(natürlich ist sie schon recht heiss)
Es gibt keine neuen Beiträge.
